Immuneering Corporation
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-56.0M | $-61.0M | $-53.5M | $-50.5M | $-33.5M | $-17.0M |
| Depreciation & Amortization | $324.5K | $355.8K | $322.8K | — | — | — |
| Depreciation | — | $355.8K | $322.8K | $247.2K | $45.5K | $24.3K |
| Amortization | $29.3K | $29.3K | $29.3K | $30.1K | — | — |
| Stock-Based Compensation | $6.3M | $6.5M | $5.7M | $4.1M | $1.8M | $1.1M |
| Net Cash from Operating Activities | $-45.3M | $-55.0M | $-49.0M | $-44.1M | $-30.9M | $-14.6M |
| Investing Activities | ||||||
| Capital Expenditures | $142.2K | $84.9K | $342.7K | $742.5K | $60.8K | $53.4K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-88.7M | $26.4M | $7.3M | $41.8M | $-75.6M | $-53.4K |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $226.6M | $5.3M | $28.4M | $19.0K | $144.3M | $38.0M |
| Net Change in Cash | $92.5M | $-23.3M | $-13.2M | $-2.3M | $37.8M | $23.3M |
| Free Cash Flow | $-45.5M | $-55.1M | $-49.3M | $-44.8M | $-30.9M | $-14.7M |